Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA Inks Exclusive Distribution Deal with BioSequence

NEW YORK (GenomeWeb) – Belgium-based OncoDNA today announced it has reached a distribution agreement with BioSequence, a Spanish personalized cancer genomics firm.

Under the terms of the agreement, BioSequence will become the exclusive Spanish distributor of OncoDNA's clinical oncology molecular diagnostics. OncoDNA offers OncoDeep Dx, which links specific genes to targeted cancer treatments, as well as other clinical cancer panels to measure translocations and protein presence and activity.

"BioSequence is a partner of choice to improve OncoDeep's use and awareness in Spain," Michäel Herman, OncoDNA's business development manager, said in a statement.

"We were very impressed by the OncoShare web platform," which offers clinicians clinically relevant interpretations of tumors sequencing results, said Adriana Terrádez, BioSequence's business development manager.

OncoDNA is affiliated with the Institute of Pathology and Genetics in Belgium.

In September 2014, OncoDNA signed an exclusive distribution deal in Greece with Istomedica.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.